Tag: Pakistan

Posted on

Pritzker Military Museum & Library Announces Finalists in International Design Competition for the Cold War Veterans Memorial

Somers, Wisconsin, Sept. 21, 2021 (GLOBE NEWSWIRE) — In April 2021, the Pritzker Military Museum & Library, located in Chicago, launched an international competition for the new Cold War Veterans Memorial to be built in Somers, Wisconsin. After reviewing an impressive number of inspiring design concepts, four finalists have been selected to advance to Stage II of the competition. The Cold War Veterans Memorial will be a critical piece of the Pritzker Archives and Memorial Park Center (PAMPC) currently under development.

“In missions on and off the battlefield, Americans of all stripes made immense sacrifices in defense of our national interest. They deserve to be recognized, and the weight of this era deserves to be understood. This Memorial will provide a place where their contributions are honored,” said Col. Jennifer Pritzker, Founder of the Pritzker Military Museum & Library.

The four finalists are representatives from the U.S., Italy, Japan, and Jordan. These individuals and groups achieved the highest scores against strict criteria, including individuality, relevance, and conceptualization. The design challenge was to provide a conceptual design for the Cold War Veterans Memorial that embraces the mission statement, exemplifies the guiding vision, and achieves the design goals. The finalists include:

  • INFINITE LIFE – Michele De Lucchi con Francesco Forcella (project architect), Nicholas Bewick, Junmei Liu, Emanuele Novembre, Guido Tarantola, Mayya Sargsyan of AMDL CIRCLE in Milan, Italy
    • Although this Memorial project was born out of the importance of respecting and honoring those that served during the Cold War period, we also see its relevance as a heroic symbol towards our continually evolving universe and the existence of human life.

For this reason, we have chosen not only the metaphor of infinity, by evoking the ‘Moebius Loop or Orbit’ in our design concept, but also to create an experience and place from which to think about our complex global interrelationships, in the hope that they can find a harmony that links every single person and preserves the physical environment in which we all live.

  • THE CONFLICT – Mai Abu-Shanab and Jalal  Al-Sadi of  m+j architect studio atelier in Amman, Jordan
    • This cold war memorial is intended to honor individuals and groups and give a permanent recognition to accomplishments, as quietly made, by countless individuals and groups as they pursued the expansion of freedom and democracy, creating a place for reflection and remembrance, inspiring the public to perceive freedom for centuries to come.
  • ORBITS OF TIME – Jenny Wu and Dwayne Oyler of Oyler Wu Collaborative in Los Angeles, California, USA
    • The proposed design envisions a memorial that embodies the ideals and mission of Memorial Park, making more tactile a context that can’t be measured in a single name or event: only in glimpses of history. Within these glimpses is layered a timeline of both personal and collective experiences emblematic of the Cold War – a paradigm that rebalances the interconnected narratives of American innovation and service.
  • ETERNAL CIRCULATION – Shinsaku Munemoto of Shinsaku Munemoto & Associates, Architects in Kyoto, Japan
    • This memorial intends to preserve the memories, records, and achievements of the veterans in perpetuity. By uncovering the layer of land, one space separates into two. The space of the “past” underneath meets the layers of the veterans’ work and time, where one can relive the veterans’ history and memories of the Cold War. The satellite dish formed above forges the “present” space to transmit the histories and memories. Through the hole opened in the unfolded land, the archive is seen, bridging the “past” records to the “present,” creating an ETERNAL CIRCULATION of education and communication.

“We were impressed by the number of inspiring design submissions that were received,” states Donald J. Stastny, FAIA, FAICP, FCIP, Competition Manager. “It wasn’t an easy decision, but we are very confident in the four finalists chosen to move forward. Their conceptual designs best embraced the mission and vision of the Memorial, and we can see them serve as an attraction for visitors.”

The Cold War Veterans Memorial’s guiding vision is to create permanent recognition that stimulates ongoing thought and study that honors American military members and civilians who served and sacrificed during the Cold War era (1945-1991). In line with the Pritzker Military Museum & Library’s mission, the Cold War Veterans Memorial aims to increase the public understanding of military history.

Stage II

In Stage II, the four groups of selected finalists will evolve their concepts for the Memorial and create more fully defined design concepts by late February 2022. Procedures in this stage include a virtual competition briefing, Q&A, mid-course review, and design exhibit.

The Competition Leadership Group will conduct an individual review of each design submittal and provide an advisory report of its findings to the Jury. The Jury will analyze each design and determine whether the integrity of the design concept embodied in the Stage I entry has been maintained in the Stage II design submittal and how it addresses the mission, vision, and design goals for the Memorial. The winning design will be announced publicly in March 2022.

View the finalists’ submissions here. All information on the design competition, including the design manual, Jury process, regulations, and schedule, can be found at coldwarveteransmemorial.org.

Pritzker Archives & Memorial Park Center

The PAMPC was created out of a need for additional space to house some of the circulating book collection and the archival collections of the Pritzker Military Museum & Library and will be completed in phases over an estimated ten years.

The first phase of the project will include the Pritzker Military Archives Center to house the collections and provide workspace for the continued curation for future exhibits; Commercial Archives based on demand where private collectors, public institutions, and others may store their archives; a facility specializing in firearms education and training; a Community Green Space expertly landscaped with walking and biking paths; and the Cold War Veterans Memorial.

About the Cold War Veterans Memorial

In line with the Pritzker Military Museum & Library’s mission, the Cold War Veterans Memorial aims to increase the public understanding of military history. It will be a lasting tribute to the courage and tenacity found in the U.S. Armed Forces and civilian personnel who faithfully and honorably served during the Cold War era, September 2, 1945, to December 26, 1991. The Memorial will be a publicly accessible display where citizens can honor, reflect, and learn about the bravery and sacrifice displayed to further our country’s freedom. To learn more, visit www.coldwarveteransmemorial.org.  

About Pritzker Archives & Memorial Park Center

Located in Somers, Wisconsin, The Pritzker Archives & Memorial Park Center supports the Pritzker Military Museum & Library’s mission of preserving the past, present, and future of the citizen soldier. This state-of-the-art archive center is a space to restore, preserve, and provide storage for collections that include books, artifacts, and other historical materials. Other components of the project include a 9,687 square-foot Gallery that will display exhibits drawing from the Pritzker Military Museum & Library in Chicago, Commercial Archives, a facility specializing in firearms education and training, Cold War Veterans Memorial, and community green space. To learn more, visit www.pritzkerarchivespark.com.

 

About the Pritzker Military Museum & Library

The Pritzker Military Museum & Library aims to increase the public’s understanding of military history, military affairs and national security by providing a forum for the study and exploration of our military – past, present, and future – with a specific focus on their stories, sacrifices, and values. With national and global reach, these spaces and events aim to share the stories of those who served and their contributions as citizen soldiers, helping citizens everywhere appreciate the relationship between the armed forces and the civilians whose freedoms they protect. A non-governmental, non-partisan organization, the Museum & Library features diverse collections, scholarly initiatives, and public programs from its flagship center in downtown Chicago to its world-class research center and park currently under construction in Somers, Wisconsin.

Erika Davis
Pritzker Archives & Memorial Park Center 
erika.davis@tawani.net
Posted on

ConvaTec Enhances Innovation Management with Anaqua

Anaqua’s AQX platform to help global medical products group protect and optimize its valuable IP portfolios

LONDON, Sept. 21, 2021 (GLOBE NEWSWIRE) — Anaqua, the leading innovation and intellectual property management technology provider, today announced that global medical products and technologies group ConvaTec will use Anaqua’s AQX platform to help more effectively manage their valuable patent and trademark portfolios.

The agreement further strengthens Anaqua’s position in the medical solutions markets, with a growing number of clients from these sectors collaborating with Anaqua as their preferred IP management provider.

With operations in more than 100 countries, ConvaTec is a global medical and technologies company focused on therapies for the management of chronic conditions, with leading market positions in advanced wound care, ostomy care, continence care, critical care, and infusion care. ConvaTec products provide a range of clinical and economic benefits including infection prevention, protection of at-risk skin, improved patient outcomes and reduced total cost of care.

Christina Allegrini, Vice President, Deputy General Counsel & Global Head of Intellectual Property at ConvaTec, said: “Our company vision is to pioneer trusted medical solutions to improve the lives we touch. As part of this, one of our key strategic pillars is to innovate in our work and solutions, supported by increased investment in R&D. Therefore, it is critically important that we manage our innovation and IP effectively and efficiently – and Anaqua will help ensure we do that.”

ConvaTec will use Anaqua’s AQX platform for patent and trademark management, annuities and renewals (in conjunction with Anaqua Services), and patent analytics through integration with Anaqua’s AcclaimIP.

Bob Romeo, CEO of Anaqua, said: “We are proud to be working with and supporting ConvaTec, a company driven by innovation to better serve people around the world in need of advanced medical care. For our part, we look forward to helping ConvaTec protect their innovation and IP management needs. We are also delighted to add another global company to our growing portfolio of clients in the healthcare and life sciences sectors.”

About Anaqua
Anaqua, Inc. is a premium provider of integrated intellectual property (IP) management technology solutions and services. Anaqua’s AQX platform combines best practice workflows with big data analytics and tech-enabled services to create an intelligent environment designed to inform IP strategy, enable IP decision-making, and streamline IP operations. Today, nearly half of the top 100 U.S. patent filers and global brands, as well as a growing number of law firms worldwide use Anaqua’s solutions. Over one million IP executives, attorneys, paralegals, administrators, and innovators use the platform for their IP management needs. The company’s global operations are headquartered in Boston, with offices across the U.S., Europe, and Asia. For additional information, please visit anaqua.com, or on LinkedIn.

About ConvaTec
ConvaTec is a global medical products and technologies company focused on therapies for the management of chronic conditions, with leading market positions in advanced wound care, ostomy care, continence and critical care, and infusion care. Headquartered in the UK, the company has operations in more than 100 countries and almost 10,000 employees worldwide. ConvaTec products provide a range of clinical and economic benefits including infection prevention, protection of at-risk skin, improved patient outcomes and reduced total cost of care. To learn more about ConvaTec, please visit convatecgroup.com.

Company Contact:
Amanda Hollis
Associate Director, Communications
Anaqua
617-375-2626
ahollis@Anaqua.com
Posted on

United States Institute of Peace Announces Finalists for 2021 Women Building Peace Award on the International Day of Peace

WASHINGTON, Sept. 21, 2021 /PRNewswire/ — The United States Institute of Peace (USIP) is proud to announce the finalists for the 2021 Women Building Peace Award on the International Day of Peace.

This prestigious global award is given each year to a woman peacebuilder who has made a major contribution to peace in her country.

This year, USIP received nominations from over 30 countries.

After careful review and consideration, a council of distinguished experts and leaders has selected the following finalists: Tabassum Adnan from Pakistan, Josephine Ekiru from Kenya, Teresita Gaviria from Colombia, Waldistrudis Hurtado from Colombia, Tatiana Mukanire from the Democratic Republic of the Congo, Esther Omam from Cameroon, Nyachangkouth Tai from South Sudan, Jayne W. Waithitu from Kenya, and Rani Yan Yan from Bangladesh.

The recipient of this year’s award will be announced at a ceremony on October 20, 2021, at USIP’s iconic campus on the National Mall in Washington D.C.

“Throughout the world, women play leading roles in preventing conflict, reducing violence and ending wars,” said Lise Grande, USIP’s president and CEO. “This is our chance to celebrate and elevate women who make the difference.”

“These women face enormous odds on a daily basis, often risking their lives for peace,” said Megan Beyer, co-chair of the selection council. “We stand in profound awe of their courage.”

“Each of the women we have selected as finalists embodies the bravery, leadership and commitment to community and country that this award recognizes,” said Marcia Carlucci, co-chair of the council.

“Reading the stories of these women is humbling, inspiring and energizing,” said Nancy Lindborg, honorary chair. “Their efforts will inspire generations of women peacebuilders.”

Congress founded USIP in 1984 as an independent, nonpartisan, national institute to prevent and end violent conflict abroad and uphold the United States’ fundamental commitment to peace.

For information on the award, visit: www.usip.org/womenbuildingpeace

For information on USIP, visit: https://www.usip.org/about

Logo – https://mma.prnewswire.com/media/1274028/United_States_Institute_of_Peace_Logo.jpg

Posted on

کامیابی سے منعقد ہونے والی17 ویں سی آئی ایس ایم ای ایف کا مقصد دنیا بھر میں ایس ایم ایز کو فوائد اور مواقع فراہم کرنا تھا

گوانگژو، چین 20ستمبر 2021 /ژن ہوا-ایشیا نیٹ / –17ویں چائنا انٹرنیشنل  اسمال اینڈ میڈیم انٹرپرائز کا میلہ (سی ایس ایم ای ایف)16ستمبر تا 19ستمبر تک جنوبی چین کے صوبہ گوانگڈانگ کے دارالحکومت گوانگژو میں منعقد ہوا۔اس میلے نے 30سے زائد ممالک اور خطوں سے کمپنیوں کو شرکت کے لیے اپنی جانب متوجہ کیا۔یہ ایک زبردست پلیٹ فارم ہےاور ایس ایم ایز کو اندرون ملک اور بیرون ملک میں تعاون اور ترقی کا معیار بڑھانے کے نئے مواقع فراہم کرتاہے۔

روبوٹک ہاتھ ،خودکار گائیڈڈ گاڑیاں،مختلف مصنوعات نظروں کو دعوت دیتی ہے۔

تقریباً 1000کمپنیاں، جو یا تو مخصوص ٹیکنالوجی  میں سبقت رکھتی ہے،یا   ریفائنڈ مصنوعات اور تکنیک،نایاب اشیائ  یا سہولیات،یا ٹیکنالوجی اوریا پیداواری طریقے میں اختراعات،کرنے والی کمپنیوں نے سی آئی ایس ایم ای ایف میں حصہ لیا۔انھوں نے زیادہ تر بہترین تیاری اور مصنوعی ذہانت ،سازوسامان کی تیاری،الیکٹرانک معلومات ،بائیو میڈیسن،اور غذا اور زراعت جیسی صنعتی شعبوں پر توجہ دی ۔

شاندار نمائشوں کے علاوہ،کاروبار کےترقی کے مواقع اور سرگرمیوں کے تبادلے کی تمام اقسام بھی قابل توجہ ہیں۔سی آئی ایس ایم ای ایف نے سرگرمیوں کے ایک سلسلے کا بندوبست کیا جس کا ہدف نمائشی صنعتی شعبے ہیں،جن میں 12سپلائی اور ڈیما نڈ  کی ڈاکنگ سرگرمیاں،4موضوعاتی سرگرمیاں،3سرحد پار کاروباری معاہدے طے کرانے کی سرگرمیاں اور بیرون ملک نمائش کنندگان کے لیے 6تشہیری سرگرمیاں،اس امید کے ساتھ کہ نمائش کنندگان اور خریدار وں کو مزید جامع اور پر اثر سہولیات فراہم کیں جائے۔

گوانگژو کی کیمسون ٹریڈ کمپنی لمیٹیڈ پہلی بار سی آئی ایس ایم ای ایف میں حصہ لے رہی ہے۔کیمسون الیکٹرواسٹیٹک پاوٗڈر کوٹنگ ایریا میں مہارت رکھتی ہے،اور اپنے صارفین کو ذہین خودکار کوٹنگ اسکیم اور سہولیات فراہم کرتی ہے۔کیمسون کے ریسرچ اور ڈیولپمنٹ ڈائریکٹر شو گن کا کہناتھا ’’سی آئی ایس ایم ای ایف ہمارے جیسی خاص ٹیکنالوجی والی کمپنیوں کو ایک زبردست پلیٹ فارم مہیا کرتا ہے۔ایک طرف،ہمارے پاس موقع ہے کہ ہم اپنی مصنوعات اور برانڈ کی تشہیر کریں۔اور دوسر ی طرف، یہ ہمیں دوسرے شعبوں سے منفرد ٹیکنالوجی کے بارے میں سیکھنے میں مدد کرتاہے،جو پھر ہم یاد کر کے اپنے شعبے میں استعمال کرتے ہیں،اور صارفین کو بہتر سہولیات فراہم کرتے ہیں۔‘‘

رونمائی،لین دین،تبادلہ،تعاون۔سی آئی ایس ایم ای ایف ایک ایسے اہم پلیٹ فارم کے طور پر کام کرتا ہے جو دنیا بھر کے ایس ایم ایز کے لیے بنایاگیاہے۔یہ کمپنیوں کو سپلائر اور خریدار کے مابین تعاون کے لیے معلومات اور کاروباری ،اور تکنیکی تبادلے کے مواقع فراہم کرتاہے۔اسی دوران،یہ نمائش چین کے ابلاغ کے فروغ کی اور اندرون و بیرون ملک ایس ایم ایز کے مابین تعاون کی جانب زبردست راہ دکھاتاہے،اور کثیر الجہتی تجارت کا مشورہ دیتاہے۔

ایس ایم ایز کے لیے بین الاقوامی تعاون سمٹ،نمائش کے ساتھ مل کر،عالمی سطح پر ایس ایم ایز کے حصول کےقابل غورایک  منصوبے کاباقاعدہ اعلان کیا،جس کی مالیت 826.3بلین یوآن ہے۔سیمیناروں کا ایک سلسلہ رکھا گیا،جن میں ایس ایم ای کی حکمت عملیوں پر وزیروں کی سطح پر ایک راوٗ نڈ ٹیبل سیمینار تھا،جس میں ان تجربات کا تبادلہ کیاگیا کہ کس طرح ایس ایم ایز کی مشکلات کو بہتر طریقے سے حل کیاجائے۔

کئی نمائش کنندگان کے لیے،ایس ایم ایز کی یہ زبردست بین الاقوامی تقریب ان کو عالمی کاروباری سرگرمیوں کے ساتھ جڑنے کو مزید بڑھائیں گی اور باہمی فوائد اور عام ترقی حاصل کرنے میں مدد کرے گی۔گوانگڈانگ جیٹن روبوٹ اینڈ آٹومیشن کمپنی لمیٹیڈ نے اس میلے میں نئی خودکار گائیڈڈ  گاڑیاں پہلی بار متعارف کرائیں۔کمپنی کے ڈپٹی جنرل منیجر وانگ میکوئی کا خیال ہے کہ سی آئی ایس ایم ای ایف مصنوعات کی تشہیر کے لیے ایک اچھا موقع فراہم کرتاہے۔ان کا کہناتھا’’ہم چاہتے ہیں کہ مزیدلوگ ہماری مصنوعات کے بارے میں جانیں، اور یہ بہت اہم ہے۔‘‘

ذریعہ : سی آئی ایس ایم ای ایف

Posted on

Adagio Therapeutics Provides COVID-19 Antibody Program Updates as well as Business Highlights and Second Quarter 2021 Financial Results

New Data Supporting Potential of ADG20 for Both the Treatment and Prevention of COVID-19 to be Presented at IDWeek 2021

Patient Population in Global EVADE Phase 2/3 Clinical Trial of ADG20 Expanded following IDMC Assessment

$355.8 Million IPO Completed to Fund Continued Advancement of Portfolio of Antibody-based Solutions for Infectious Diseases with Pandemic Potential

WALTHAM, Mass., Sept. 20, 2021 (GLOBE NEWSWIRE) — Adagio Therapeutics, Inc., (Nasdaq: ADGI) a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today reported updates on its lead COVID-19 antibody program, ADG20, as well as recent business highlights and second quarter 2021 financial results.

“Across the globe, COVID-19 continues to be a significant health crisis affecting nearly every age group. With the continued emergence of new variants, broadly neutralizing therapies that can be used for both the treatment and prevention of the disease are critical to address the current endemic as well as potential future outbreaks,” said Tillman Gerngross, Ph.D., co-founder and chief executive officer of Adagio. “Our team is working closely with our global CRO partners on the execution of our ongoing global clinical trials of ADG20, STAMP and EVADE, while also preparing for the anticipated worldwide commercialization of ADG20, if approved.

“ADG20 is a highly differentiated antibody that we are advancing through pivotal trials for both the treatment and prevention of COVID-19. We are pleased by the recent assessment of unblinded data by the IDMC for the EVADE trial, and their support of our plans to expand enrollment to include adolescents and pregnant or nursing women,” said Lynn Connolly, M.D., Ph.D., chief medical officer of Adagio. “To date, we have generated a compelling data package for ADG20 that includes broad neutralization of the original SARS-CoV-2 virus and the known variants of concerns in in vitro models as well as a favorable pharmacokinetic and tolerability profile in our Phase 1 trial. Further, at this year’s IDWeek, we will release additional data from our Phase 1 trial as well as details regarding our dose selection process for treatment and prevention, which we believe further support the important role this novel antibody can play in combatting the ongoing pandemic.”

ADG20 COVID-19 Program Highlights

  • New ADG20 Data to be Presented in Multiple Posters during IDWeek: At the IDWeek 2021 Virtual Conference, Adagio plans to present additional data highlighting the potential for ADG20 to provide protection from COVID-19 for up to one year based on its extended half-life in humans combined with its broad and potent neutralizing ability demonstrated in laboratory testing. In addition, the data support the evaluation of a 300mg dose, delivered as a single intramuscular injection, in the ongoing Phase 2/3 STAMP (treatment) and EVADE (prevention) global clinical trials. The data will be presented in multiple posters, which will be available to registered attendees on the virtual platform throughout the duration of the conference, being held from September 29 – October 3, 2021. The presentations include:
    • 1086: A Whole-Body Quantitative System Pharmacology Physicologically-Based Pharmacokinetic (QSP/PBPK) Model that a priori Predicts Intramuscular (IM) Pharmacokinetics of ADG20: an Extended Half-life Monoclonal Antibody Being Developed for the Treatment and Prevention of Coronavirus Disease (COVID-19)
    • 633: Preliminary Results from a Phase 1 Single Ascending-Dose Study Assessing Safety, Serum Viral Neutralizing Antibody Titers (sVNA), and Pharmacokinetic (PK) Profile of ADG20: an Extended Half-Life Monoclonal Antibody Being Developed for the Treatment and Prevention of Coronavirus Disease (COVID-19)
    • 1089: Use of a Whole-Body Quantitative System Pharmacology Physiologically-Based Pharmacokinetic (QSP/PBPK) Model to Support Dose Selection of ADG20: an Extended Half-Life Monoclonal Antibody Being Developed for the Prevention of Coronavirus Disease (COVID-19)
    • 1088: A Whole-Body Quantitative System Pharmacology Physiologically-Based Pharmacokinetic (QSP/PBPK) Model to Support Dose Selection of ADG20: an Extended Half-Life Monoclonal Antibody Being Developed for the Treatment of Coronavirus Disease (COVID-19)
  • Patient Population Expanded in EVADE following IDMC Data Assessment: The independent data monitoring committee (IDMC) for the EVADE Phase 2/3 trial of ADG20 for the prevention of COVID-19 recently provided a recommendation to expand Phase 3 trial enrollment to include adolescents 12 years and older and pregnant or nursing women, as well as a decrease in the protocol-specified, in-clinic post injection monitoring time. The IDMC’s recommendations were based on their review of unblinded safety and tolerability data through the Day 28 post-treatment visit from 200 participants enrolled in the Phase 2 lead-in portion of the trial.
  • Partnership with Biocon Biologics Expands the Reach of a Potent and Broadly Neutralizing COVID-19 Antibody Treatment to Patients in India and Select Emerging Markets: In the second quarter of 2021, Adagio partnered with Biocon Biologics Ltd. to combat the ongoing COVID-19 crisis in southern Asia. The partnership provides Biocon rights to manufacture and commercialize an antibody therapy based on ADG20 in India and additional select emerging markets based on the commercial manufacturing process developed for ADG20. As part of the agreement, Biocon will be granted access to data from Adagio’s Phase 2/3 clinical trials as well as its anticipated Emergency Use Authorization package and other regulatory submissions to support approval or emergency authorization in India and other select emerging markets.

Recent Business Highlights

  • David Hering, Global COVID-19 Vaccine Expert, Appointed as Chief Operating Officer: Adagio recently appointed David Hering as the company’s chief operating officer. Mr. Hering joins Adagio from Pfizer, where he most recently served as the global mRNA business lead, a business specifically created to manage global COVID-19 efforts as well as future vaccines utilizing mRNA technology, and led the launch of the first-ever COVID-19 vaccine in the United States. Prior to his most recent role at Pfizer, Mr. Hering was president, North America at Pfizer, where he led a 700-person organization across a portfolio of vaccine products for COVID-19 and meningococcal and pneumococcal diseases.
  • $355.8 Million Initial Public Offering (IPO) Successfully Completed: In August 2021, Adagio sold 20,930,000 shares of common stock, including the full exercise of the underwriters’ option to purchase an additional 2,730,000 shares of common stock at a public offering price of $17.00 per share. The gross proceeds of the offering, before underwriting discounts and commissions and other offering expenses payable by Adagio, were approximately $355.8 million.
  • Collaboration with Scripps: Adagio entered into an exclusive research agreement with The Scripps Research Institute to identify broadly protective vaccine candidates for the prevention of influenza and beta coronaviruses.
  • Board of Directors Expanded with Industry Leaders to Support Future Growth: Adagio recently announced appointments of three industry veterans and area experts to its board of directors:
    • Tom Heyman, former president of the Johnson & Johnson Development Corporation (JJDC);
    • Anand Shah, M.D., former deputy commissioner for medical and scientific affairs at the U.S. Food and Drug Administration (FDA); and
    • Michael S. Wyzga, president of MSW Consulting, Inc. and former CFO of Genzyme

Second Quarter 2021 Financial Results

  • As of June 30, 2021, Adagio had cash, cash equivalents and marketable securities of $392.5 million, which includes net proceeds from its Series C financing completed in April. Pro forma cash, cash equivalents and marketable securities as of June 30, 2021 is $719.6 million after giving effect to our initial public offering which closed on August 10, 2021.
  • Research & development expenses including in-process research and development for the second quarter of 2021 were $37.6 million.
  • Selling, general & administrative expenses for the second quarter of 2021 were $7.1 million.
  • Net Loss for the second quarter was $44.7 million, or $0.18 per share.

About ADG20
ADG20, a monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses, is being developed for the prevention and treatment of COVID-19, the disease caused by SARS-CoV-2. ADG20 was designed and engineered to possess high potency and broad neutralization against SARS-CoV-2 and additional clade 1 sarbecoviruses, by targeting a highly conserved epitope in the receptor binding domain. ADG20 displays potent neutralizing activity against the original SARS-CoV-2 strain as well as all known variants of concern. ADG20 has the potential to impact viral replication and subsequent disease through multiple mechanisms of action, including direct blocking of viral entry into the host cell (neutralization) and elimination of infected host cells through Fc-mediated innate immune effector activity. ADG20 is administered by a single intramuscular injection, and was engineered to have a long half-life, with a goal of providing both rapid and durable protection. Adagio is advancing ADG20 through multiple clinical trials on a global basis.

About Adagio Therapeutics

Adagio (Nasdaq: ADGI) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company’s portfolio of antibodies has been optimized using Adimab’s industry-leading antibody engineering capabilities and is designed to provide patients and clinicians with a powerful combination of potency, breadth, durable protection (via half-life extension), manufacturability and affordability. Adagio’s portfolio of SARS-CoV-2 antibodies includes multiple, non-competing broadly neutralizing antibodies with distinct binding epitopes, led by ADG20. Adagio has secured manufacturing capacity for the production of ADG20 with third-party contract manufacturers through the completion of clinical trials and, if approved by regulatory authorities, through initial commercial launch. For more information, please visit www.adagiotx.com.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates,” “believes,” “expects,” “intends,” “projects,” and “future” or similar expressions are intended to identify forward-looking statements. Forward-looking statements include statements concerning, among other things, the timing, progress and results of our preclinical studies and clinical trials of ADG20, including the timing of our planned IND submissions, initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available and our research and development programs; our ability to obtain and maintain regulatory approvals for, our product candidates; our ability to identify patients with the diseases treated by our product candidates and to enroll these patients in our clinical trials; our manufacturing capabilities and strategy; and our ability to successfully commercialize our product candidates. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from the results described in or implied by the forward-looking statements, including, without limitation, those risks described under the heading “Risk Factors” in Adagio’s prospectus filed with the Securities and Exchange Commission (“SEC”) on August 6, 2021 and in Adagio’s future reports to be filed with the SEC, including Adagio’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2021. Such risks may be amplified by the impacts of the COVID-19 pandemic. Forward-looking statements contained in this press release are made as of this date, and Adagio undertakes no duty to update such information except as required under applicable law.

Contacts:

Media Contact:
Dan Budwick, 1AB
Dan@1abmedia.com

Investor Contact:
Monique Allaire, THRUST Strategic Communications
monique@thrustsc.com

ADAGIO THERAPEUTICS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(UNAUDITED)

(In thousands, except share and per share amounts)

June 30,
2021		 December 31,
2020
Assets
Current assets:
Cash and cash equivalents(1) $ 392,509 $ 114,988
Prepaid expenses and other current assets 3,550 2,394
Total current assets 396,059 117,382
Deferred offering costs 1,933 —
Total assets $ 397,992 $ 117,382
Liabilities, Convertible Preferred Stock and Stockholders’ Deficit
Current liabilities:
Accounts payable $ 10,716 $ 8,153
Accrued expenses 27,181 4,919
Total current liabilities 37,897 13,072
Early-exercise liability 8 11
Total liabilities 37,905 13,083
Commitments and contingencies
Convertible preferred stock (Series A, B and C) $0.0001 par value; 16,944,484 shares authorized, issued and outstanding at June 30, 2021; 12,647,934 shares authorized, issued and outstanding at December 31, 2020; aggregate liquidation preference of $505,399 and $169,900 at June 30, 2021 and December 31, 2020, respectively 504,711 169,548
Stockholders’ deficit:
Common stock, $0.0001 par value; 150,000,000 shares authorized at June 30, 2021 and December 31, 2020; 5,599,240 shares issued and outstanding at June 30, 2021; 28,193,240 shares issued and 5,593,240 shares outstanding at December 31, 2020 1 1
Treasury stock, at cost; 0 shares and 22,600,000 shares at June 30, 2021 and December 31, 2020, respectively — (85 )
Additional paid-in capital 4,067 154
Accumulated deficit (148,692 ) (65,319 )
Total stockholders’ deficit (144,624 ) (65,249 )
Total liabilities, convertible preferred stock and stockholders’ deficit $ 397,992 $ 117,382

(1)     Pro forma cash, cash equivalents and marketable securities as of June 30, 2021 is $719.6 million after giving effect to our issuance and sale of 20,930,000 shares of our common stock in our initial public offering at the price of $17.00 per share after deducting underwriting discounts, commissions and estimated offering costs which closed on August 10, 2021.

ADAGIO THERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(UNAUDITED)

(In thousands, except share and per share amounts)

Three Months
Ended
June 30,		 Six Months
Ended
June 30,		 Period from
June 3, 2020
(Inception) to
June 30,
2021 2021 2020 (3)
Operating expenses:
Research and development(1) $ 35,067 $ 69,204 $ 48
Acquired in-process research and development(2) 2,500 3,500 —
Selling, general and administrative 7,124 10,695 50
Total operating expenses 44,691 83,399 98
Loss from operations (44,691 ) (83,399 ) (98 )
Other income (expense):
Interest income 23 32 —
Other expense (5 ) (6 ) —
Total other income (expense), net 18 26 —
Net loss and comprehensive loss $ (44,673 ) $ (83,373 ) $ (98 )
Net loss per share attributable to common stockholders, basic and
diluted		 $ (0.18 ) $ (0.66 ) $ —
Weighted-average common shares outstanding, basic and diluted 249,769 125,574 21,250,000

(1)   Includes related-party amounts of $247 for the three months ended June 30, 2021, $435 for the six months ended June 30, 2021 and $0 for the period from June 3, 2020 (inception) to June 30, 2020.
(2)   Includes related-party amounts of $2,500 for the three months ended June 30, 2021, $3,500 for the six months ended June 30, 2021 and $0 for the period from June 3, 2020 (inception) to June 30, 2020.
(3)   The results for the period from June 3, 2020 (inception) to June 30, 2020 are the same for the three and six months ended June 30, 2020.

Posted on

FDA Clears First Technology to Distinguish between Bacterial and Viral Infections Using the Body’s Immune Response – The MeMed BV® Test and MeMed Key® Platform

FDA Clears First Technology to Distinguish between Bacterial and Viral Infections Using the Body’s Immune Response – The MeMed BV® Test and MeMed Key® Platform

  • MeMed BV is a first-of-its kind test that decodes the immune response to accurately distinguish between bacterial or viral infections within minutes
  • MeMed Key is a pioneering platform that enables rapid and sensitive measurements of multiple proteins at the point-of-need
  • The MeMed technology suite enables better informed antibiotic treatment decisions, an essential tool in the fight against the global threat of resistant bacteria

HAIFA, Israel, Boston, MA; September 20th, 2021 – MeMed, a leader in the emerging field of advanced host-response technologies, today announces that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for use of the MeMed BV® test on the point-of-need platform MeMed Key® to help healthcare providers distinguish between bacterial and viral infections. The technology has been cleared for both children and adults.

Bacterial and viral infections are often clinically indistinguishable, leading to the prescription of antibiotics for the treatment of viral infections, for which they are ineffective. Antibiotic misuse drives the emergence of antimicrobial resistance (AMR), one of the biggest healthcare challenges of our time.
The novelty of MeMed’s technology is that it decodes the body’s immune response to infection, the ‘host response’, rather than focusing on detecting the presence of a microbe. This allows robust diagnosis when the infection site is inaccessible or unknown, even when the pathogen is undetectable using conventional tests, or when the cause of infection are emerging new pathogens. It enables better informed antibiotic treatment decisions, an essential tool in the fight against resistant bacteria.

“For those of us who care for acutely ill children, we have been waiting decades for accurate, rapid diagnostics to confidently guide the care of moderately ill children without a clear focus of infection or recognizable viral illness. This novel test offers promise to help differentiate those children with self-limited viral illness from those with possible bacterial infection, thereby supporting the judicious use of antibiotics,” said Rich Bachur, MD, Professor of Pediatrics and Emergency Medicine, Harvard Medical School, and Chief, Division of Emergency Medicine, Boston Children’s Hospital.

“It has been a decade long journey to reach this point from concept to impacting patient lives,” said Dr. Eran Eden, MeMed’s co-founder and CEO. “This FDA clearance is a breakthrough moment in the field of advanced host-response and could not have been achieved without the dedication of the MeMed team, our clinical partners in the US and around the globe, and the support of the US Department of Defense and EU Commission.”

Sergey Motov, MD, Professor of Emergency Medicine, Maimonides Medical Center, New York, said: “Host-response technologies are a new frontier in the management of patients with infectious diseases, with great potential to improve patient outcomes. Every day, I see adults with a complicated medical history presenting to the emergency room with a suspected respiratory tract infection. A technology like MeMed BV can significantly aid in their management.”

“We are now using MeMed BV in my department routinely to aid in determining whether a child with fever has a bacterial or viral infection. For example, we recently had a complicated case of a young child with fever but without a clear source. MeMed BV helped in early identification of a severe bacterial infection, that would otherwise be masked by viral PCR detection, lead to a change in the course of treatment, and made a big difference in the patient’s outcome,” said Dr Adi Klein, Director of the Pediatric Division, Hillel Yaffe Medical Center and Head of the Israeli Clinical Pediatric Society. “Introducing MeMed’s technology has had a significant impact on our medical practice, enabling us to be better stewards of antibiotics and improving patient outcomes.”

FDA clearance was based on a multi-center blinded clinical validation study enrolling over 1,000 children and adults and addresses goals laid out in the US National Action Plan for Combating Antibiotic Resistant Bacteria. The test provides highly accurate results with Area Under the Curve of 90% and 97% (primary and secondary endpoints). MeMed has established its US base in Boston and is ramping up commercial activities to ensure broad availability of its products across the US.

About MeMed
Our mission is to translate the immune system’s complex signals into simple insights that transform the way diseases are diagnosed and treated, profoundly benefiting patients and society. To learn more about MeMed and our solutions, please visit http://www.me-med.com

About MeMed BV®
MeMed BV® is a first-of-its-kind immune-based protein signature test, developed and validated over the course of decade-long collaborations with leading academic and commercial partners. It provides physicians with an indispensable tool to help distinguish between bacterial and viral infections across multiple pathogens, even if the infection site is inaccessible or unknown. MeMed BV® measures and computationally integrates the levels of three immune system proteins: TRAIL, IP-10 and CRP. When run on the MeMed Key® platform, MeMed BV® provides a result within 15 minutes. MeMed BV® has been independently validated on thousands of patients and the results have been published in leading peer-reviewed journals (including Pediatrics, The Lancet ID,  PLOS One, BMJ Peds and European Journal of Clinical Microbiology & Infectious Diseases). The MeMed BV® test has received a CE Mark in Europe and AMAR clearance from the Israeli Ministry of Health.

About MeMed Key®
MeMed Key® is a pioneering technology platform, enabling highly sensitive measurements of multiple proteins, within minutes, at the point of need. It opens the way to quantification of a vast array of human proteins in healthy and disease states, where and when it actually matters. The MeMed Key® development program has been partially funded by the US Department of Defense and the EU Commission. MeMed Key® has received a CE Mark in Europe and AMAR clearance from the Israeli Ministry of Health.

MeMed Contacts:
Adee Mor, VP Marketing, MeMed
pr@me-med.com
Kfir Emmer, CFO, MeMed
kfir.emmer@me-med.com

Media relations contact:
Consilium Strategic Communications MeMed@consilium-comms.com

Please click here to see the full release in Hebrew